ArticleAnalytical and bioanalytical chemistry2026
Parallel fluorescence interrogation of multichannel chips for rapid point-of-care testing.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of rapid and reliable point-of-care testing (POCT) devices requires optical platforms capable of combining fast readout, sensitivity, and robustness. In this work, a fully integrated optoelectronic platform for fluorescence detection in multichannel microfluidic chips is presented, based on a parallel optical interrogation strategy. The platform employs a diffractive optical element (DOE) to achieve simultaneous excitation of multiple microchannels and an array of waveguide absorption filters (WAFs) for parallel fluorescence collection and efficient rejection of excitation light. This configuration eliminates mechanical scanning and enables optical interrogation within a few seconds. The platform is integrated with a microfluidic handling system and dedicated control software, allowing automated execution of immunoassays. Stability and reproducibility were demonstrated through repeated chip loading experiments, showing low variability across microchannels. As a proof of concept, a fluorescence sandwich immunoassay for C-reactive protein (CRP) was implemented in plasma, achieving a limit of detection of 0.32 µg mL⁻
Indexed as
Identifiers
42570022What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.